Joel Swerdel is an Associate Director of Epidemiology Analytics at Janssen Research and Development, a Johnson and Johnson company. He is involved in many epidemiological research projects where he designs novel approaches for the use of standard OHDSI methods. He has recently completed a project using predictive modeling to determine patients in end-of-life care. He is currently working on designing a standard approach for developing and evaluating diagnostic phenotypes.
Prior to joining Janssen Research and Development, Joel was at the Rutgers School of Public Health where he conducted epidemiology research in the areas of cardiovascular disease and cancer. Prior to Rutgers, Joel was at Bristol-Myers Squibb in drug development research. Joel received a BA from Rutgers, an MS from the Medical College of Wisconsin, and an MPH from the Rutgers School of Public Health. He received his doctorate in epidemiology from the Rutgers School of Public Health where he used patient-level prediction to develop models for predicting incident heart failure in subjects previously diagnosed with atrial fibrillation.